Paratek Presents New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia by Measures of Disease Severity

Data Presented During “New Insights in Acute Pulmonary Infections” Oral Session at American Thoracic Society 2018 International Conference
BOSTON, May 22, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today presented a new analysis of the Phase 3 OPTIC study of omadacycline, its first in class aminomethylcycline, versus moxifloxacin, a fluoroquinolone, for the treatment of community-acquired bacterial pneumonia (CABP). OPTIC efficacy results were presented by measures of disease severity. The data showed similar, high rates of resp…


Leave a Reply

Your email address will not be published.